Browse the evidence

Inflammation indirectly causes muscle atrophy by dysregulating the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to excessive glucocorticoid release, which further inhibits muscle protein synthesis and promotes proteolysis.

Managing stress and underlying inflammation is crucial because chronic stress and inflammation can trigger hormonal responses (cortisol) that actively break down muscle. Medical interventions that stabilize the HPA axis or reduce inflammatory cytokines may help preserve muscle mass.

Myostatin (MSTN) levels are increased by inflammatory factors (TNF-α, IL-6) and act as a negative regulator of muscle mass by activating the Smad2/3 pathway, which upregulates E3 ubiquitin ligases (MuRF1, Atrogin-1) and inhibits satellite cell recruitment.

High levels of inflammatory cytokines can increase Myostatin, a protein that naturally limits muscle growth. In chronic disease, this system is overactive, contributing to muscle loss. Therapies targeting Myostatin or its receptors are being investigated to counteract this loss.

Mechanical unloading (disuse) induces skeletal muscle atrophy primarily through a dual mechanism: suppression of the IGF-1-Akt-mTOR protein synthesis pathway and upregulation of the ubiquitin-proteasome system (specifically MuRF1/MAFbx E3 ligases) driven by FOXO transcription factors.

If you are experiencing forced inactivity (like casting or bed rest), your muscles will shrink due to suppressed growth signals (mTOR) and increased breakdown signals (FOXO/MuRF1). While you cannot fully stop this, engaging in any available resistance exercise (even isometric) or ensuring adequate protein intake may help mitigate the rate of loss by keeping these pathways partially active.

Oxidative stress (ROS overproduction) and Calcium (Ca2+) overload are major triggers that exacerbate disuse-induced muscle atrophy by promoting protein breakdown and inhibiting synthesis.

Managing oxidative stress and calcium handling may help protect muscle during periods of inactivity. Antioxidants and strategies to maintain muscle membrane integrity might be beneficial, though the paper notes these are 'potential countermeasures' requiring more research.

GLP-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and inhibiting the NF-κB pathway, independent of glycemic control.

GLP-1 medications like semaglutide and liraglutide do more than just lower blood sugar; they actively reduce systemic inflammation by blocking key inflammatory pathways (NF-κB) and lowering pro-inflammatory cytokines. This benefit exists regardless of whether your blood sugar improves, suggesting these drugs may help with inflammatory conditions beyond diabetes.

Obesity induces low-grade chronic inflammation in white adipose tissue (WAT) via adipocyte death (apoptosis/necroptosis), which recruits pro-inflammatory macrophages (forming crown-like structures) and triggers systemic insulin resistance and metabolic syndrome.

Obesity is not just about storing fat; it is an active inflammatory state. Excess fat, especially visceral fat, leads to adipocyte death, which triggers an immune response (inflammation) that blocks insulin signaling. To improve metabolic health, strategies must address this underlying inflammation, not just caloric intake, by supporting adipose tissue health and reducing cytokine-driven resistance.

TNF and NF-κB signaling pathways directly inhibit insulin signaling by phosphorylating IRS-1, thereby causing insulin resistance; neutralizing TNF or inhibiting IKKβ improves glucose homeostasis.

Chronic inflammation in fat tissue directly blocks insulin's ability to work by interfering with key signaling proteins (IRS-1). Reducing this inflammation, whether through weight loss, exercise, or potentially anti-inflammatory strategies, can restore insulin sensitivity.

Slow-wave sleep (N3 stage) is the primary driver of glymphatic clearance, facilitating the removal of neurotoxic waste products like amyloid-beta and tau from the brain.

Prioritize getting enough slow-wave sleep (deep sleep) to allow your brain to clear out metabolic waste like amyloid-beta. This happens naturally during the N3 stage of sleep. Protecting this sleep phase is a critical preventative measure against neurodegenerative diseases like Alzheimer's.

Obesity-induced adipose tissue fibrosis, driven by unresolved inflammation and hypoxia, restricts adipose expandability and contributes to insulin resistance and resistance to weight loss.

Focus on preventing fat tissue damage (fibrosis) rather than just losing weight. Strategies that reduce inflammation and improve vascularization in fat tissue may be more metabolically beneficial than weight loss alone, especially in severe obesity.

Promoting angiogenesis (healthy vascularization) in adipose tissue reduces inflammation and fibrosis, whereas suboptimal vascularization leads to hypoxia and insulin resistance.

Maintaining good blood flow to fat tissue through exercise and healthy lifestyle may help prevent the stiffening (fibrosis) of fat tissue, which is linked to insulin resistance.

Bariatric surgery-induced weight loss does not resolve adipose tissue fibrosis and may even increase ECM deposition, potentially contributing to metabolic deterioration during weight rebound.

Weight loss surgery reduces fat mass but may leave fat tissue stiff and inflamed. Long-term management should focus on maintaining metabolic health, not just weight loss, to mitigate fibrosis-related risks.

High luminal glucose concentrations trigger the translocation of the facilitative transporter GLUT2 to the brush border membrane (BBM) of enterocytes, thereby increasing the capacity for D-glucose absorption.

Your small intestine is designed to absorb glucose more efficiently when you consume a high-glucose meal. It does this by moving specific transporters (GLUT2) to the surface of the cells facing the gut lumen. This is a normal, healthy physiological response to maximize nutrient uptake from carbohydrate-rich foods.

SGLT1 abundance in the brush border membrane increases in response to high luminal glucose, mediating high-capacity glucose absorption.

When you eat foods high in glucose, your body increases the number of SGLT1 transporters on the surface of your intestinal cells. This allows your body to absorb more glucose efficiently from your meal.

GLUT5 is the primary facilitative transporter responsible for D-fructose absorption in the small intestine.

Your body uses a specific transporter called GLUT5 to absorb fructose (fruit sugar) from your small intestine. This is a dedicated pathway distinct from the primary glucose absorption mechanisms.

Skeletal muscle-derived myokines (Irisin, Cathepsin B) and metabolites (Lactate, β-Hydroxybutyrate, Kynurenic Acid) mediate exercise-induced neuroprotection, angiogenesis, and memory enhancement via blood-brain barrier signaling.

Regular physical activity sends chemical signals from your muscles to your brain that protect neurons, improve memory, and boost mood. You don't need to know the specific molecules; consistent exercise is the key to activating this muscle-to-brain communication system.

Exercise-induced elevation of muscle PGC-1α shifts kynurenine metabolism toward kynurenic acid, reducing neurotoxic kynurenine accumulation and conferring resistance to stress-induced depression.

For those struggling with stress or depression, regular endurance exercise helps your muscles process tryptophan in a way that prevents neurotoxic buildup in the brain. This biological mechanism offers protection against stress-induced mood disorders.

Skeletal muscle BMAL1 regulates sleep homeostasis and NREM sleep duration, demonstrating that peripheral tissue clocks influence central sleep processes.

Regular exercise helps synchronize your body's internal clocks, including those in your muscles, which in turn helps regulate your sleep duration and recovery. Consistent physical activity supports better sleep architecture.

Fibroblast Growth Factor 21 (FGF21) analogues improve plasma lipid profiles in humans but lack glucose-lowering efficacy in type-2 diabetic patients, contrasting with robust glucose and lipid improvements observed in mouse models.

If you are considering FGF21-based therapies for diabetes, understand that current evidence suggests they may help with blood fats (lipids) but are not expected to lower blood sugar levels in humans, unlike what was seen in laboratory mice. This highlights the importance of human-specific clinical data over animal studies.

Elevated circulating FGF21 levels in humans are associated with obesity, insulin resistance, and metabolic syndrome, suggesting a state of 'FGF21 resistance' similar to insulin resistance.

In obesity, your body produces high levels of FGF21 as a stress response, but you may become resistant to its effects. This resistance is linked to insulin resistance and metabolic syndrome. Managing weight and metabolic health may help restore sensitivity to this hormone.

Perivascular adipose tissue (PVAT) dysfunction, characterized by reduced adiponectin secretion and increased pro-inflammatory cytokines, directly contributes to hypertension and insulin resistance by losing its anti-contractile effect on blood vessels.

Focus on reducing visceral fat rather than just total body weight. Strategies that promote 'beiging' of adipose tissue (like cold exposure) or reduce inflammation may help improve vascular health and blood pressure, even if overall weight loss is modest. Prioritize metabolic health markers over BMI.

Insulin resistance promotes the development of Alzheimer's disease pathology through multiple interconnected mechanisms including reduced cerebral glucose metabolism, impaired amyloid-beta clearance via competition for insulin-degrading enzyme (IDE), and increased amylin deposition.

Maintaining metabolic health, specifically insulin sensitivity, is a critical strategy for reducing Alzheimer's risk. This involves managing blood sugar, avoiding excessive refined carbohydrates, and engaging in regular physical activity to improve insulin signaling. For those with existing insulin resistance or type 2 diabetes, aggressive management of these conditions may help protect brain health.

Testosterone treatment in older men with low testosterone increases coronary artery noncalcified plaque volume, but was not associated with more cardiovascular or prostate adverse events over 12 months.

If you are an older man with confirmed low testosterone, testosterone therapy may increase your coronary artery noncalcified plaque volume, but this was not associated with more cardiovascular or prostate adverse events over 12 months. The treatment involves daily application of a gel, with dose adjustments to keep levels in the normal range for young men. Long-term safety requires more data.

Metformin improves healthspan and reduces early mortality from age-related diseases (cardiovascular disease, cancer, diabetes) but does not directly extend maximum lifespan in humans.

If you have Type 2 Diabetes or are at high risk, metformin is a standard, safe, and effective treatment that significantly reduces your risk of heart disease, cancer, and early death. While it may not make you live to 100, it helps you stay healthy longer by managing blood sugar and protecting your blood vessels. Discuss with your doctor if it is appropriate for you, keeping in mind potential stomach upset which can often be managed.

Mid-day time-restricted feeding (mTRF), defined as an 8-hour eating window between 11:00 and 20:00, does not significantly improve insulin sensitivity, fasting glucose, body mass, or inflammation compared to ad libitum eating in healthy non-obese adults.

If you prefer eating later in the day (e.g., 11 AM to 7 PM), be aware that this specific mid-day TRF window may not improve insulin sensitivity, reduce body weight, or lower inflammation compared to normal eating habits in healthy, non-obese individuals. If metabolic health is your goal, shifting your eating window to end earlier (by 3 PM) may be more effective.